Importance Breast cancer will be diagnosed in 12% of women in the United States over the
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …

Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of
this disease. This Series article reviews the main achievements so far in the treatment of …

Importance ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains
typically incurable with optimal treatment undefined in later lines of therapy. The chimeric …

Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Background In patients with metastatic breast cancer that is positive for human epidermal
growth factor receptor 2 (HER2), progression-free survival was significantly improved after …

Background In the randomised, parallel assignment, open-label, phase 3 TH3RESA study,
progression-free survival was significantly longer with trastuzumab emtansine versus …

Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4,
has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to …

ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …

Background Patients with progressive disease after two or more HER2-directed regimens for
recurrent or metastatic breast cancer have few effective therapeutic options. We aimed to …